KMDA Stock Overview
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kamada Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪5.09 |
| 52 Week High | ₪6.53 |
| 52 Week Low | ₪4.08 |
| Beta | 0.24 |
| 1 Month Change | -11.17% |
| 3 Month Change | -12.09% |
| 1 Year Change | 13.62% |
| 3 Year Change | -16.69% |
| 5 Year Change | -11.32% |
| Change since IPO | -44.97% |
Recent News & Updates
Shareholder Returns
| KMDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | -2.5% | -3.2% |
| 1Y | 13.6% | -3.7% | 19.3% |
Return vs Industry: KMDA exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: KMDA underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| KMDA volatility | |
|---|---|
| KMDA Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KMDA's share price has been volatile over the past 3 months.
Volatility Over Time: KMDA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 378 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
| KMDA fundamental statistics | |
|---|---|
| Market cap | US$293.77m |
| Earnings (TTM) | US$8.28m |
| Revenue (TTM) | US$142.52m |
35.5x
P/E Ratio2.1x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMDA income statement (TTM) | |
|---|---|
| Revenue | US$142.52m |
| Cost of Revenue | US$87.03m |
| Gross Profit | US$55.49m |
| Other Expenses | US$47.21m |
| Earnings | US$8.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 38.94% |
| Net Profit Margin | 5.81% |
| Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparison